AVTX Form 3 — Boyd Taylor files initial statement with zero holdings

Rhea-AI Filing Summary

Boyd Taylor, identified as Chief Business Officer and a director, filed an initial Form 3 for Avalo Therapeutics, Inc. (AVTX) reporting the event date 10/01/2025. The filing states no securities are beneficially owned by the reporting person. The form was signed under power of attorney by Donald R. Reynolds on 10/06/2025. The submission confirms an initial disclosure with no ownership to report.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Boyd Taylor

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/01/2025

3. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Donald R. Reynolds, by Power of Attorney	10/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Boyd Taylor disclose on the Form 3 for AVTX?

The filing states that Boyd Taylor (Chief Business Officer and director) does not beneficially own any securities of Avalo Therapeutics as of 10/01/2025.

What is the reporting date on the Form 3 for Avalo Therapeutics (AVTX)?

The event date listed on the Form 3 is 10/01/2025.

Who signed the Form 3 and when was it signed?

The form was signed under power of attorney by Donald R. Reynolds on 10/06/2025.

Does the Form 3 show any derivative or non-derivative securities owned?

No. The filing explicitly states "No securities are beneficially owned."

What roles does the reporting person hold at Avalo Therapeutics?

The filing indicates the reporting person is an Officer (Chief Business Officer) and a Director of Avalo Therapeutics.